Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vebreltinib + PD-1 Inhibitors in HCC and RCC
NCT03655613Phase 2Terminated
- Sponsor
- Apollomics, Inc.
- Start
- Sep 2018
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of vebreltinib in hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) (2 cohorts), sponsored by Apollomics, Inc. Primary endpoint: Dose Limiting Toxicities. Started Sep 2018; status: terminated.
02
Drugs
vebreltinib
03
Conditions
hepatocellular carcinoma (HCC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03655613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03655613.